200 related articles for article (PubMed ID: 38348455)
1. Osseous implications of proton pump inhibitor therapy: An umbrella review.
Alanazi AS; Almutairi H; Gupta JK; Mohanty D; Rath D; AlOdan AA; Mahal A; Khatib MN; Gaidhane S; Zahiruddin QS; Rustagi S; Satapathy P; Serhan HA
Bone Rep; 2024 Mar; 20():101741. PubMed ID: 38348455
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
5. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
6. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors, bone and phosphocalcic metabolism.
Philippoteaux C; Paccou J; Chazard E; Cortet B
Joint Bone Spine; 2024 Mar; 91(5):105714. PubMed ID: 38458487
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibitors on bone mineral density: A systematic review and meta-analysis of observational studies.
Aleraij S; Alhowti S; Ferwana M; Abdulmajeed I
Bone Rep; 2020 Dec; 13():100732. PubMed ID: 33299906
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of vitamin D in relation to bone health.
Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
[TBL] [Abstract][Full Text] [Related]
10. Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review.
Teperikidis E; Boulmpou A; Potoupni V; Kundu S; Singh B; Papadopoulos C
Acta Cardiol; 2023 Nov; 78(9):980-988. PubMed ID: 37431972
[TBL] [Abstract][Full Text] [Related]
11. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis.
Jeridi D; Pellat A; Ginestet C; Assaf A; Hallit R; Corre F; Coriat R
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887860
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
14. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
Salvo EM; Ferko NC; Cash SB; Gonzalez A; Kahrilas PJ
Aliment Pharmacol Ther; 2021 Jul; 54(2):129-143. PubMed ID: 34114655
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors for chronic obstructive pulmonary disease.
Kikuchi S; Imai H; Tani Y; Tajiri T; Watanabe N
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013113. PubMed ID: 32844430
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
17. Association and Mechanisms of Proton Pump Inhibitors Use with Type-2 Diabetes Mellitus Incidence in Adults: A Systemic Review and Metaanalysis.
Chenchula S; Sharma P; Ghanta MK; Amerneni KC; Rajakarunakaran P; Saggurthi P; Chandra MB; Gupta R; Chavan M
Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38243950
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.
Bahtiri E; Islami H; Hoxha R; Qorraj-Bytyqi H; Rexhepi S; Hoti K; Thaçi K; Thaçi S; Karakulak Ç
J Bone Miner Metab; 2016 Sep; 34(5):571-9. PubMed ID: 26209167
[TBL] [Abstract][Full Text] [Related]
19. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials.
Veettil SK; Sadoyu S; Bald EM; Chandran VP; Khuu SAT; Pitak P; Lee YY; Nair AB; Antony PT; Ford AC; Chaiyakunapruk N
Br J Clin Pharmacol; 2022 Feb; 88(4):1551-1566. PubMed ID: 34622475
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
